Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
about
Getting to the Heart of the Matter: An Overview of Cardiac Toxicity Related to Cancer TherapyToxicological evaluation of a rotenone derivative in rodents for clinical myocardial perfusion imaging.EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockadeCancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Animal models in studies of cardiotoxicity side effects from antiblastic drugs in patients and occupational exposed workersCardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Cardio-oncology: cardiovascular complications of cancer therapy.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinibNanomolar-Potency Small Molecule Inhibitor of STAT5 Protein.The new revolution in toxicology: the good, the bad, and the ugly.Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.Targeted Therapy for Medullary Thyroid Cancer: A Review.
P2860
Q26797138-DD0D8928-B87B-4D2E-BA53-2554766A66F0Q33655776-9EA45E80-70D5-4033-951B-B30813C835E4Q34859831-2AC75FD7-EA03-467C-9205-9084CC974A40Q36451899-059F1866-6EBE-4FAE-98A9-F86E959F543DQ37631325-2B516E0A-DF6F-45F4-AF01-81F441008F38Q38101883-81A33F08-7658-4260-9803-BD9CDE0A73DBQ38665281-B4571EC0-5935-4D9E-A34F-68CF5DAD2E00Q39344380-4F3B0FDC-7512-4501-BDB4-05BEDEF8A608Q41304682-8BBACCCC-A8DE-4B49-973A-EFEA5783252EQ43009401-225835A4-0176-4ECB-B6F0-E9D328DCD24EQ45421942-7A0B109D-F67D-4799-9B97-A022A114E21CQ47965108-6005C4D2-4286-46C1-A5A7-8A542B87393AQ49328959-946EB955-2B6E-4963-9023-10883A81C6CC
P2860
Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Tyrosine kinase inhibitor (TKI ...... aluation and clinical outcome.
@en
type
label
Tyrosine kinase inhibitor (TKI ...... aluation and clinical outcome.
@en
prefLabel
Tyrosine kinase inhibitor (TKI ...... aluation and clinical outcome.
@en
P356
P1476
Tyrosine kinase inhibitor (TKI ...... aluation and clinical outcome.
@en
P2093
Baichun Yang
Thomas Papoian
P304
P356
10.1002/JAT.2813
P407
P577
2012-09-10T00:00:00Z